QLGN Overview

Shareholder Approval: Shareholders approved all proposals, confirming Faraday Future as the majority and controlling shareholder of Qualigen Therapeutics, with an estimated 63% equity ownership including affiliates.

Corporate Renaming and Ticker Change: The company will officially rename itself AIxCrypto Holdings, Inc. and adopt the ticker symbol AIXC during a ceremony at Nasdaq on November 20, 2025.

Strategic Transformation Announcement: At the renaming ceremony, AIxCrypto will unveil a new business model, ecosystem structure, and a three-year development roadmap aimed at positioning itself as a leader in the AI × Web3 era.

Governance Restructuring: Faraday Future will designate the majority of the reconstituted Board of Directors, completing governance updates to align with the company's new strategic direction and technology focus.

Rebranding Announcement: Qualigen Therapeutics Inc. will rebrand as AIxCrypto following a stockholder meeting on November 12, 2025, as it shifts focus to Web3 and crypto asset initiatives.

Strategic Roadmap: AIxCrypto plans to launch the public beta of its BesTrade DeAI Agent by the end of November and release its EAI RWA Utility Token Whitepaper, aiming for significant milestones by the end of 2025.

C10 Treasury Expansion: The company aims to grow its C10 Treasury to $50 million in assets under management and strengthen its role as a core reserve asset in the Web3 ecosystem.

Global Growth and Ecosystem Development: AIxCrypto will initiate a global user growth campaign for its BesTrade DeAI Agent and plans to launch crypto ecosystem tokens on leading exchanges to create a sustainable on-chain value growth system.

Intel's Strong Performance: Intel Corporation's shares rose 8.4% in pre-market trading after reporting third-quarter revenue of $13.65 billion and adjusted earnings of 23 cents per share, both exceeding analyst expectations.

Notable Gainers: Several stocks saw significant pre-market gains, including Qualigen Therapeutics (up 106.7%), Wellgistics Health (up 74.4%), and Inhibrx Biosciences (up 54.6%), driven by strategic partnerships and positive clinical trial results.

Major Losers: Picard Medical experienced a sharp decline of 65.3%, while Scienture Holdings and MultiSensor AI also faced significant drops of 30.3% and 27.1%, respectively, following previous surges.

Other Market Movements: Ford Motor Company and Nextracker reported positive earnings, contributing to their pre-market gains, while Deckers Outdoor Corporation and Newmont Corporation saw declines despite reporting better-than-expected earnings.

Partnership Announcement: Qualigen Therapeutics has partnered with BitGo to manage a crypto treasury strategy, marking a significant shift from its traditional biotech focus.

Stock Performance: Following the announcement, QLGN shares surged over 100% in pre-market trading, indicating strong investor interest after a period of weak stock performance.

Analyst Ratings: Despite the positive market reaction, an AI analyst from TipRanks rates QLGN as Underperform due to concerns over weak revenue, heavy losses, and financial strain.

Future Outlook: The analyst suggests that recent investments and leadership changes could potentially lead to improvements for the company moving forward.

Partnership Announcement: Qualigen Therapeutics Inc. has partnered with BitGo to manage its multi-asset cryptocurrency treasury strategy, significantly boosting its stock price.

Stock Performance: Following the announcement, QLGN shares surged over 60% in after-hours trading, building on a 5.37% increase during regular trading hours.

Investment Strategy: The biotech company plans to invest in a diversified basket of the top 10 cryptocurrencies, utilizing BitGo’s over-the-counter desk for liquidity and custody.

Market Context: Despite the recent surge, QLGN's stock has seen a year-to-date decline of 16.15%, although it shows a stronger price trend in the short and medium term according to Benzinga’s Edge Stock Rankings.

Market Overview: The crypto market recently faced a significant downturn, with over $16 billion in leveraged positions liquidated, primarily due to geopolitical tensions and excessive market leverage, which the company views as a necessary "stress test" rather than a fundamental collapse.

CXC10's Strategic Response: Qualigen Therapeutics' CXC10 is seizing this market pullback as an opportunity to begin purchasing high-quality assets, leveraging a systematic investment framework to manage risks and identify undervalued cryptocurrencies for future growth.